Can you get Mounjaro with a BMI of 26?

What does the Mounjaro licence actually say about BMI?

Tirzepatide (sold in the UK as Mounjaro by Eli Lilly) is licensed for weight management in adults with a BMI of 30 or above, or with a BMI of 27 to 29.9 where at least one weight-related health condition is also present. Conditions that qualify under the licence include type 2 diabetes, high blood pressure, dyslipidaemia and obstructive sleep apnoea, among others. The NHS medicines page for tirzepatide sets this out clearly.

A BMI of 26 sits below the 27 floor of even the condition-based route. That is not an arbitrary line. The clinical trials that generated Mounjaro's safety and efficacy data enrolled participants at higher BMIs; the licence reflects where the evidence was gathered. Prescribing outside those parameters without strong clinical justification would be difficult to defend, and a responsible prescriber will not do it.

It is also worth understanding what BMI measures and what it does not. It is a population-level screening tool, not a precise measure of body fat or metabolic health. Two people can share an identical BMI and have very different health profiles. That is exactly why prescribers treat it as one input, not the whole story, but the licensed thresholds remain the starting point for any assessment.

Does having a health condition change things at BMI 26?

The short answer is: not for the standard private prescription route. The condition-based threshold is BMI 27, not BMI 26. Even with a diagnosis of hypertension or prediabetes, a BMI of 26 falls below the minimum the licence defines for that route.

Where ethnic background becomes relevant is the NICE-recommended adjustment. NICE technology appraisal TA1026 recommends applying BMI thresholds that are 2.5 kg/m² lower for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. For the condition-based route, that adjustment brings the qualifying BMI down to around 24.5, which would include a BMI of 26. This is a clinically recognised adjustment, not a loophole; it reflects evidence that metabolic risk presents at lower BMIs in these populations.

If this applies to you, it is genuinely worth discussing at consultation. A prescriber cannot assume your background; you would need to raise it and have your conditions and history reviewed in full. Our FAQs page covers some of the eligibility questions that come up most often.

What are the options if you don't currently qualify?

Finding out your BMI rules you out can be frustrating, particularly if you feel your weight is affecting your health. A few practical things are worth knowing.

First, BMI is calculated from height and weight at the time of measurement. If you have recently lost weight or if your weight fluctuates, your BMI at a formal video consultation (where live weight verification takes place) may differ from a home estimate. That is not a suggestion to manipulate anything, it is just a note that BMI is a snapshot, not a fixed characteristic.

Second, the BMI 27 threshold page explains in detail how the condition-based route works for people on the boundary, and if you are wondering whether a BMI of 28 opens up additional options with Mounjaro, or how eligibility is assessed at a BMI of 29, those pages walk through what applies at each point, and the full BMI eligibility guide for Mounjaro covers every threshold, including the ethnic-background adjustments, in one place. Reading those before booking a consultation will help you arrive with the right information to hand.

Third, lifestyle approaches remain both valid and evidence-supported at a BMI of 26. The weight management overview on this site covers what is available, including options that do not require a prescription. The NHS BMI calculator at nhs.uk is a useful reference point for tracking your own measurements accurately.

It is also worth knowing that our guidance on Mounjaro at a BMI of 25 explains why that figure sits outside the licensed routes and what the realistic options are from that starting point.

How does the cost picture look if your BMI does qualify in future?

Mounjaro is not available on the NHS for most people yet; the phased rollout is focused on higher BMIs and multiple health conditions. Private treatment through a regulated pharmacy is the current route for the majority. Pricing has shifted considerably since Eli Lilly adjusted its UK list price in late 2025, the Lilly price increase page has the detail on what changed and why typical private prices now range more widely by dose.

One thing worth knowing if you are planning ahead: Mounjaro starts at 2.5mg, a dose chosen for tolerability rather than therapeutic effect, and titrates upward over several months. The pen lives in the fridge between doses (the fridge door is a common spot) and is replaced monthly. The monthly cost varies by the dose you reach, which is another reason to factor the full treatment journey into any financial planning, not just the starting price. The treatment page shows current pricing transparently, with no hidden fees.